135
Participants
Start Date
January 31, 2007
Primary Completion Date
October 31, 2008
Study Completion Date
October 31, 2008
Ibandronate
Ibandronate orally (tablet) at a dose of 150 mg once per month
placebo
Placebo orally (tablet) at a dose of 150 mg once per month
GSK Investigational Site, Duncansville
GSK Investigational Site, Bathesda
GSK Investigational Site, Wheaton
GSK Investigational Site, Richmond
GSK Investigational Site, Salem
GSK Investigational Site, Beckley
GSK Investigational Site, Asheville
GSK Investigational Site, Charleston
GSK Investigational Site, Decatur
GSK Investigational Site, Atlanta
GSK Investigational Site, Gainsville
GSK Investigational Site, Miami
GSK Investigational Site, Miami
GSK Investigational Site, West Palm Beach
GSK Investigational Site, Clearwater
GSK Investigational Site, Palm Harbor
GSK Investigational Site, Louisville
GSK Investigational Site, Indianapolis
GSK Investigational Site, Madison
GSK Investigational Site, Woodbury
GSK Investigational Site, Chicago
GSK Investigational Site, Peoria
GSK Investigational Site, Champaign
GSK Investigational Site, Springfield
GSK Investigational Site, Tulsa
GSK Investigational Site, Dallas
GSK Investigational Site, Longmont
GSK Investigational Site, Tucson
GSK Investigational Site, Albuquerque
GSK Investigational Site, Beverly Hills
GSK Investigational Site, Palm Desert
GSK Investigational Site, Walnut Creek
GSK Investigational Site, Oakland
GSK Investigational Site, Greenbrae
GSK Investigational Site, Portland
GSK Investigational Site, Seattle
GSK Investigational Site, Seattle
GSK Investigational Site, Birmingham
GSK Investigational Site, Kansas City
GSK Investigational Site, South Portland
GSK Investigational Site, Providence
Collaborators (1)
GlaxoSmithKline
INDUSTRY
Hoffmann-La Roche
INDUSTRY